转移性激素敏感性前列腺癌的前列腺放疗:STOPCAP系统综述与荟萃分析
该系统综述与荟萃分析纳入HORRAD和STAMPEDE两项已完成试验共2126例转移性激素敏感性前列腺癌患者,比较前列腺放疗联合雄激素剥夺治疗与单纯雄激素剥夺治疗。汇总结果显示前列腺放疗未改善总生存和无进展生存,但改善生化进展和无失败生存,疗效随转移负荷不同而异。作者结论认为低转移负荷患者应考虑前列腺放疗。
要点
- 汇总分析显示前列腺放疗未显著改善总生存(HR=0.92,95%CI 0.81-1.04,p=0.195)。
- 前列腺放疗改善生化进展(HR=0.74,95%CI 0.67-0.82)和无失败生存(HR=0.76,95%CI 0.69-0.84)。
- 转移负荷与放疗效果存在交互作用(交互HR=1.47,95%CI 1.11-1.94,p=0.007),骨转移少于5处的患者3年生存改善7%。
核心结论
- 对于转移性激素敏感性前列腺癌且转移负荷低的患者,应考虑前列腺放疗。
研究设计与样本
- 采用前瞻性框架(适应性荟萃分析框架FAME),在试验结果未知前预设方法,广泛检索合格试验并向研究者获取发表前、未发表及协调后的结果。
- 纳入将患者随机分配至前列腺放疗联合雄激素剥夺治疗(ADT)或单纯ADT的试验;识别到一项进行中试验(PEACE-1)和两项已完成试验(HORRAD和STAMPEDE),对后两项共2126例男性(占合格者的90%)进行汇总分析。
- 使用固定效应荟萃分析合并前列腺放疗对生存、无进展生存(PFS)、无失败生存(FFS)、生化进展及亚组交互作用的危险比(HR)。
主要发现
- 汇总结果显示前列腺放疗未显著改善总生存(HR=0.92,95%CI 0.81-1.04,p=0.195)或无进展生存(HR=0.94,95%CI 0.84-1.05,p=0.238)。
- 前列腺放疗改善生化进展(HR=0.74,95%CI 0.67-0.82,p=0.94×10-8)和无失败生存(HR=0.76,95%CI 0.69-0.84,p=0.64×10-7),相当于3年约10%的获益。
- 前列腺放疗的效果随转移负荷不同而异,该模式在各试验和结局指标中一致,包括生存(骨转移<5处 vs ≥5处;交互HR=1.47,95%CI 1.11-1.94,p=0.007)。
- 骨转移少于5处的男性3年生存改善7%。
关键数值与推荐
- 骨转移<5处与≥5处的交互作用HR=1.47(95%CI 1.11-1.94,p=0.007)。
- 骨转移少于5处的男性3年生存改善7%。
- 生化进展HR=0.74(95%CI 0.67-0.82,p=0.94×10-8),无失败生存HR=0.76(95%CI 0.69-0.84,p=0.64×10-7),相当于3年约10%获益。
临床怎么用
- 作者结论认为,对于转移性激素敏感性前列腺癌且转移负荷低的患者,应考虑前列腺放疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Many trials are evaluating therapies for men with metastatic hormone-sensitive prostate cancer (mHSPC). OBJECTIVE: To systematically review trials of prostate radiotherapy. DESIGN, SETTING, AND PARTICIPANTS: Using a prospective framework (framework for adaptive meta-analysis [FAME]), we prespecified methods before any trial results were known. We searched extensively for eligible trials and asked investigators when results would be available. We could then anticipate that a definitive meta-analysis of the effects of prostate radiotherapy was possible. We obtained prepublication, unpublished, and harmonised results from investigators. INTERVENTION: We included trials that randomised men to prostate radiotherapy and androgen deprivation therapy (ADT) or ADT only. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Hazard ratios (HRs) for the effects of prostate radiotherapy on survival, progression-free survival (PFS), failure-free survival (FFS), biochemical progression, and subgroup interactions were combined using fixed-effect meta-analysis. RESULTS AND LIMITATIONS: We identified one ongoing (PEACE-1) and two completed (HORRAD and STAMPEDE) eligible trials. Pooled results of the latter (2126 men; 90% of those eligible) showed no overall improvement in survival (HR=0.92, 95% confidence interval [CI] 0.81-1.04, p=0.195) or PFS (HR=0.94, 95% CI 0.84-1.05, p=0.238) with prostate radiotherapy. There was an overall improvement in biochemical progression (HR=0.74, 95% CI 0.67-0.82, p=0.94×10-8) and FFS (HR=0.76, 95% CI 0.69-0.84, p=0.64×10-7), equivalent to ∼10% benefit at 3yr. The effect of prostate radiotherapy varied by metastatic burden-a pattern consistent across trials and outcome measures, including survival (<5, ≥5; interaction HR=1.47, 95% CI 1.11-1.94, p=0.007). There was 7% improvement in 3-yr survival in men with fewer than five bone metastases. CONCLUSIONS: Prostate radiotherapy should be considered for men with mHSPC with a low metastatic burden. PATIENT SUMMARY: Prostate cancer that has spread to other parts of the body (metastases) is usually treated with hormone therapy. In men with fewer than five bone metastases, addition of prostate radiotherapy helped them live longer and should be considered.
引用
- Burdett S, Boevé LM, Ingleby FC, et al. Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. Eur Urol. 2019. PMID: 30826218. doi:10.1016/j.eururo.2019.02.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。